Next Generation Antibody Therapeutics Market
The increasing number of technological developments in the healthcare industry is one of the major factors fuelling the surge in the demand for next-generation antibody therapeutics market solutions throughout the globe. For instance, there have been major developments in the healthcare technologies over the last few years such as the development of bispecific antibodies (BsAbs), ADC technologies, and glycoengineered antibody. These advancements have significantly increased the application area of the antibody therapeutics. The other major factor propelling the demand for next-generation antibody therapeutics solutions is the increasing prevalence of chronic diseases across the world.
ADCs are widely considered to be much safer and effective than the conventionally used antibodies for cancer treatment as these are made by combining a biologically active cytotoxic drug and a monoclonal antibody for targeting the tumor cells. This also plays a major role in overcoming the challenges occurring because of the limited utilization of the monoclonal antibody therapeutics. Due to these factors, the global next-generation antibody therapeutics market is expected to exhibit huge growth in the coming years.
There are different types of technologies adopted for the development of next-generation antibody therapeutics solutions such as antibody drug conjugates (ADCs), Fc engineered antibodies, biospecific antibodies (BsAbs), antibody fragments and antibody-like proteins (ALPs & AF), and biosimilar antibody (Ab) products. Out of these, the ADCs recorded the highest usage in the last few years. The Fc engineered antibodies are expected to register rapid growth in demand in the coming years.
The biggest trend currently being witnessed in the next-generation antibody therapeutics market is the rising adoption of ADC technology in various applications. It has been found that the cytotoxic nature of antibodies have potentially huge benefits in chemotherapy, which are regulated and expressed by the ADC technology in order to achieve higher specificity and enhanced efficacy. Due to the high efficiency provided by the ADCs, many biotechnology and pharmaceutical companies across the world are rapidly shifting their focus toward the development of ADCs.
Geographically, North America leads the next-generation antibody therapeutics market. This can primarily be attributed to increased antibody-based research activities, rising cases of chronic health disorders, well-developed life sciences research infrastructure, and strong presence of established players in the region.
Globally, North America is predicted to observe rapid growth in the utilization of next-generation antibody therapeutics solutions in the coming years. This is mainly attributed to the presence of major antibody therapeutics solutions developing and providing companies, rising incidence of chronic diseases, existence of well-developed life sciences research facilities and infrastructure, and the increasing implementation of government measures and policies in several countries for promoting research and development (R&D) activities in antibody therapeutics solutions, in the region.
Therefore, it can be concluded that owing to the rising technological advancements in antibody therapeutics solutions and healthcare industry, increasing incidence of chronic diseases, surging geriatric population, and the numerous benefits provided by the next-generation antibody therapeutics solutions in various healthcare applications, their demand is expected to skyrocket throughout the world in the coming years.